Trial abstract · §3
SYNCHRONIZE-CVOT — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Time to first major adverse cardiovascular event | no result held by the Institute | Not rated |
| The Institute publishes no effect estimate for a trial whose report it does not hold. | ||
§3.2Harms as reported
Table 5. Adverse events for Survodutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 52.0 | 18.0 | Phase 2 obesity, highest dose |
| Vomiting | 37.0 | 4.0 | Phase 2 obesity |
| Constipation | 29.0 | 10.0 | Phase 2 obesity |
| Increased heart rate | — | — | Dose-dependent, attributed to the glucagon arm |
| Discontinuation for adverse events | 25.0 | 5.0 | Phase 2 obesity, highest dose |
Compound Evidence Institute · CEI-TR-0060/3 · https://compoundevidence.com/trials/synchronize-cvot/results/ · retrieved 30 July 2026